22:24 , Sep 18, 2018 |  BC Extra  |  Clinical News

Sosei, Allergan to delay trials of dementia candidate

Sosei Group Corp. (Tokyo:4565) and partner Allergan plc (NYSE:AGN) have suspended clinical development of neurodegenerative candidate HTL0018318 to investigate a toxicity signal -- a rare tumor -- found in a non-human primate treated with the...
17:36 , Sep 13, 2018 |  BC Innovations  |  Translation in Brief

Keeping CRISPR on target

Editas Medicine Inc. (NASDAQ:EDIT) has developed an in silico model of Staphylococcus aureus Cas9 (SaCas9) gene editing to help it select guide RNA sequences with minimal risk of off-target effects. Editas’ lead candidate EDIT-101 is built...
00:00 , Sep 8, 2018 |  BioCentury  |  Product Development

Data distribution

TransCelerate BioPharma Inc. is taking its data sharing initiative to the next level with a new platform that will integrate clinical and preclinical data sets in a single repository and provide new analytical tools. DataCelerate,...
18:46 , Aug 31, 2018 |  BC Week In Review  |  Clinical News

Allergan uterine fibroids therapy hits regulatory setback

Allergan plc (NYSE:AGN) said FDA issued a complete response letter for its NDA for ulipristal acetate to treat abnormal uterine bleeding in women with uterine fibroids. The company said FDA requested additional information and cited...
18:13 , Aug 31, 2018 |  BC Week In Review  |  Financial News

ApoGen expands series A to $11M

Drug-resistant cancer company ApoGen Biotechnologies Inc. raised an additional $4 million on Aug. 23 from M Ventures and existing investors in its series A round, bringing the round's total to $11 million. M Ventures is...
19:34 , Aug 24, 2018 |  BC Extra  |  Politics & Policy

Allergan, Mohawk Tribe request rehearing in sovereign immunity IPR case

Allergan plc (NYSE:AGN) and the Saint Regis Mohawk Tribe filed a petition on Aug. 20 for an en banc rehearing of their patent case in front of the full U.S. Court of Appeals for the...
22:44 , Aug 21, 2018 |  BC Extra  |  Company News

Allergan uterine fibroids therapy hits regulatory setback

Allergan plc (NYSE:AGN) said FDA issued a complete response letter for its NDA for ulipristal acetate to treat abnormal uterine bleeding in women with uterine fibroids. The company said FDA requested additional information and cited...
21:40 , Aug 20, 2018 |  BC Extra  |  Company News

Management tracks: Athenex, Intra-Cellular

Cancer company Athenex Inc. (NASDAQ:ATNX) said Director of Corporate Development and Investor Relations Randoll Sze will become CFO. Neurology play Intra-Cellular Therapies Inc. (NASDAQ:ITCI) hired Suresh Durgam as SVP of late-stage clinical development and medical affairs....
21:53 , Aug 17, 2018 |  BioCentury  |  Finance

MD Anderson’s blooms

The recent launch of Magnolia Neurosciences Corp. with a $31 million series A round is the latest example of a broader effort by the University of Texas MD Anderson Cancer Center to ramp up company...
17:25 , Aug 17, 2018 |  BC Week In Review  |  Financial News

MD Anderson launches neuroscience newco with $31M series A

The University of Texas MD Anderson Cancer Center and Accelerator Life Science Partners (Seattle, Wash.) have co-founded Magnolia Neurosciences Corp. (New York, N.Y.), which launched Aug. 13 with a $31 million series A round. Eli Lilly...